Results 41 to 50 of about 8,469 (207)

Management of prolactinoma during pregnancy and postpartum

Journal of Integrated Health Sciences, 2015
Prolactinoma is classified as microprolactinoma when it measures
Om J Lakhani, Rishma Lakhani, M Desai, M Tripathi   +3 more
doaj   +1 more source

Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets

Journal of Neuroendocrinology, EarlyView.
Prolactin and dopamine modulate migraine‐relevant trigeminal pathways. Hyperprolactinemia is associated with migraine‐like headache, and preclinical studies show that prolactin enhances trigeminal excitability, particularly in females. Dopamine inhibits prolactin release and may also directly suppress trigeminovascular activity via D2 receptors in the ...
Astrid Johannesson Hjelholt, Randi Maria Hanghøj Tei, Hans Christoph Diener, Jens Otto Lunde Jørgensen   +3 more
wiley   +1 more source

Aggressive and Malignant Prolactinomas [PDF]

Neuroendocrinology, 2019
Prolactin-secreting tumors (prolactinomas) represent the most common pituitary tumor type, accounting for 47–66% of functional pituitary tumors. Prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and ...
Eyrc, Manuel D. Gahete, Luis G. Perez-Rivas, Federico Gatto, Nicoleta Cristina Olarescu, Gianluca Tamagno, Gianluca Tamagno, Maria A. Tichomirowa, Thomas Cuny   +8 more
openaire   +7 more sources

ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer

Journal of Clinical Laboratory Analysis, Volume 39, Issue 17, September 2025.
ACT001, a novel small‐molecule inhibitor, demonstrates significant antitumoral and immunomodulatory effects in NSCLC by inhibiting cell proliferation, migration, and invasion, inducing cell cycle arrest, and suppressing tumor growth. Mechanistically, it targets STAT1/STAT3, reduces PD‐L1 expression, and enhances granzyme B release in CD3+ T cells ...
Zhijing Shi, Yiman Li, Huijie Hou, Zhitao Wang, Hui Guo, Yang Yu, Yan Song, Zhe Chen   +7 more
wiley   +1 more source

Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer

MedComm, Volume 6, Issue 8, August 2025.
Mitochondrial fission and fusion are key processes in maintaining cellular health. Fission is driven by proteins like, Fis‐1, which recruits DRP‐1, to facilitate the division of mitochondria. Fusion, however, is mediated by mitofusion 1(MFN1), mitofusion 2(MFN2), and optic atrophy 1 (OPA1), which work together to merge mitochondria, allowing functional
Saloni Malla, Rabin Neupane, Saloni Sood, Noor Hussein, Mariam Abou‐Dahech, David Terrero, Charles R. Ashby Jr., R. Jayachandra Babu, Amit K. Tiwari   +8 more
wiley   +1 more source

The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma

Trials, 2021
Background First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%.
Ingrid M. Zandbergen, Amir H. Zamanipoor Najafabadi, Iris C. M. Pelsma, M. Elske van den Akker-van Marle, Peter H. L. T. Bisschop, H. D. Jeroen Boogaarts, Arianne C. van Bon, Bakhtyar Burhani, Saskia le Cessie, Olaf M. Dekkers, Madeleine L. Drent, Richard A. Feelders, Johan P. de Graaf, J. Hoogmoed, Kitty K. Kapiteijn, Melanie M. van der Klauw, Willy-Anne C. M. Nieuwlaat, Alberto M. Pereira, Aline M. E. Stades, Annenienke C. van de Ven, Iris M. M. J. Wakelkamp, Wouter R. van Furth, Nienke R. Biermasz, on behalf of the Dutch Prolactinoma Study Group   +23 more
doaj   +1 more source

Patient Participation in Urine Specific Gravity Screening for Arginine Vasopressin Deficiency in an Inpatient Neurosurgical Clinic

Clinical Endocrinology, Volume 103, Issue 2, Page 201-208, August 2025.
ABSTRACT Objective Detecting hypotonic urine (specific gravity < 1005 g/L) is crucial for the early identification of arginine vasopressin deficiency (AVP‐deficiency), a common complication after pituitary surgery. This study aimed to evaluate the agreement between urine specific gravity measurements taken by patients using urine test strips and those ...
Jeanne‐Marie Nollen, Anja H. Brunsveld‐Reinders, Nienke R. Biermasz, Marco J. T. Verstegen, Eline Leijtens, Wilco C. Peul, Ewout W. Steyerberg, Wouter R. van Furth   +7 more
wiley   +1 more source

An uncommon cause of osteoporosis

Journal of Family Medicine and Primary Care, 2018
Osteoporosis in the younger age group is an important cause of morbidity. Prolactinoma is an uncommon but reversible cause of osteoporosis. The main mechanisms of osteoporosis in prolactinoma are reduced osteoblast activity and hypogonadism. A high index
Rohit Barnabas, Basavaraj Soora Gauda, Kripa Elizabeth Cherian, Nitin Kapoor, Hesarghatta Shyamasunder Asha, Thomas Vizhalil Paul   +5 more
doaj   +1 more source

A case of giant prolactinoma and pituitary hemorrhage with the late recovery of pituitary function: A case report

SAGE Open Medical Case Reports, 2023
Hypogonadotropic hypogonadism is a common finding in patients who are diagnosed with a prolactinoma. It can be accompanied by the presence of other pituitary hormone deficits, including secondary adrenal insufficiency and central hypothyroidism.
Lakshmi P Menon, Dinesh Edem
doaj   +1 more source

MiR‐20a‐5p Inhibits Bladder Cancer Proliferation and Migration by Targeting KPNA2

Journal of Cellular and Molecular Medicine, Volume 29, Issue 16, August 2025.
ABSTRACT Bladder cancer (BC) is one of the 10 most common cancers in the world, and its recurrence and metastasis are the main causes of death in BC patients. Exploring the molecular mechanisms of BC pathogenesis and searching for new prognostic markers and therapeutic targets are important for improving patient prognosis.
Shuai Ye, Cen Liufu, Cong Yin, Tao Zhu, Jinqing He, Yuanyuan Tian, Yan Wang, Bentao Shi   +7 more
wiley   +1 more source